XTL Biopharmaceuticals Ltd.

Company Overview

Business Model: XTL Biopharmaceuticals Ltd. is an intellectual property-based company primarily engaged in AI web data collection through its wholly owned subsidiary, The Social Proxy Ltd. The Social Proxy Ltd. develops, operates, and distributes an ethical, Internet Protocol-based proxy data extraction platform for AI and Business Intelligence purposes at scale. Historically, XTL Biopharmaceuticals Ltd. was a biopharmaceutical company focused on autoimmune diseases. However, in March 2025, it sublicensed its hCDR1 asset to Biossil Inc., effectively ceasing active involvement in drug development. Revenue is generated from licensing cloud-enabled services subscriptions from The Social Proxy Ltd. platform.

Market Position: The Social Proxy Ltd. operates in the rapidly evolving and intensely competitive data collection, web data scraping, and cybersecurity industries. It offers ethical, secure, fast, reliable, and cost-effective proxy services. The company leverages proprietary 5G and 4G mobile private proxies, built on in-house hardware and software, providing an unlimited supply of Internet Protocol addresses. It claims to operate the largest raw mobile proxy network globally (without using end-user mobile devices) and employs Carrier-Grade Network Address Translation (CGNAT) technology for enhanced transparency and unlockability. The global data collection and labeling market was valued at $3.77 billion in 2024 and is projected to grow at a CAGR of 28.4% from 2025 to 2030, reaching $17.1 billion by 2030.

Recent Strategic Developments:

• August 2024: Completed the acquisition of 100% of the share capital of The Social Proxy Ltd. for a consideration including 186,479,027 ordinary shares (representing approximately 20% of XTL Biopharmaceuticals Ltd.'s issued and outstanding share capital on a non-diluted basis), $430,000 in cash, and 2,896,142 warrants exercisable upon reaching certain financial milestones.
• March 2025: Entered into an Exclusive Sublicense Agreement with Biossil Inc. (Canada) for its novel synthetic peptide, hCDR1 (Edratide). XTL Biopharmaceuticals Ltd. granted a royalty-free, exclusive, worldwide perpetual sublicense. The agreement includes cumulative payments of up to approximately $11,500,000, with $137,500 received at closing as a license issuing fee, up to $3,362,000 upon regulatory milestones, and up to $8,000,000 upon commercial milestones. Following this, XTL Biopharmaceuticals Ltd. is no longer actively involved in hCDR1 or any other drug candidate development.
• April 2025: Noam Band was appointed Chief Executive Officer of XTL Biopharmaceuticals Ltd., replacing Shlomo Shalev, who assumed the role of Chairman of the Board.
• Ongoing development and enhancement of proxy and data extraction technologies, including advanced API integrations and automation features such as Professional Data API, Social Scraper API, and SERP API.

Geographic Footprint: XTL Biopharmaceuticals Ltd.'s headquarters and primary operations are located in Israel. The Social Proxy Ltd. maintains a geographically diverse infrastructure with proxy servers deployed across the United States (New York, Florida, and Texas), Europe (Germany, Austria, the United Kingdom), and Israel. The company aims to continue expanding its global footprint to serve a wide range of client requirements.

Cross-Border Operations: XTL Biopharmaceuticals Ltd. operates through two wholly-owned subsidiaries: The Social Proxy Ltd. and Xtepo Ltd., both incorporated in Israel. Its international business activities include the worldwide sublicense of hCDR1 to Biossil Inc. (Canada). The company navigates multi-jurisdictional regulatory frameworks, including U.S. and Israeli export control and economic sanctions laws, as well as data privacy regulations such as the European Union’s General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA). The Social Proxy Inc and Social Proxy LDA, subsidiaries of The Social Proxy Ltd., are subject to a corporate tax rate of 21% in the United States and Portugal, respectively.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 0.66%
• Operating Margin: -481.6%
• Net Margin: -227.7%

Investment in Growth:

• R&D Expenditure: $98 thousand (21.7% of revenue)
• Capital Expenditures: $54 thousand (for purchase of fixed assets)
• Strategic Investments: The acquisition of The Social Proxy Ltd. involved a cash payment of $430 thousand and a loan of $400 thousand provided to The Social Proxy Ltd. prior to the acquisition.

Currency Impact Analysis: XTL Biopharmaceuticals Ltd. holds most of its cash, cash equivalents, and bank deposits in U.S. dollars. A significant portion of its operating expenses are denominated in New Israeli Shekels (NIS), exposing the company to foreign exchange risk. The company's treasury risk management policy involves holding NIS-denominated cash and short-term deposits to cover anticipated NIS-denominated liabilities for six to twelve consecutive months. A hypothetical 10% strengthening of the Group’s functional currency (U.S. dollar) against the NIS in 2024 would have resulted in a $46 thousand lower loss for the year.

Business Segment Analysis

Web Data Collection Solutions (The Social Proxy Ltd.)

Financial Performance (Year ended December 31, 2024):

• Revenue: $451 thousand
• Operating Loss: $(1,232) thousand
• Key Growth Drivers: The segment's performance is driven by the increasing global demand for real-time data extraction, cybersecurity solutions, and AI-driven analytics. Its focus on ethical, secure, fast, reliable, and cost-effective proxy services, underpinned by proprietary 5G and 4G mobile private proxies and CGNAT technology, is central to its growth strategy.

Product Portfolio:

• Proprietary 5G and 4G mobile private proxies (dedicated or rotating solutions).
• AI-powered scrapers and data API feeds, including Professional Data API, Social Scraper API, and SERP API.
• Cloud-enabled services subscriptions.

Market Dynamics: The segment operates in a highly competitive and rapidly evolving industry. Key competitors include Bright Data Ltd., Oxylabs, Smartproxy, and NetNut. Market trends emphasize privacy-first, compliant proxy solutions, transparency, legal compliance, and cybersecurity resilience. The regulatory environment is complex and evolving, with increasing scrutiny from laws like GDPR and CCPA, and challenges posed by data localization laws and anti-scraping mechanisms.

Geographic Revenue Distribution: The Social Proxy Ltd. has proxy servers deployed across the United States (New York, Florida, and Texas), Europe (Germany, Austria, the United Kingdom), and Israel. While specific revenue distribution by these geographies is not disclosed, the company's strategy includes expanding its global footprint, particularly in high-demand regions such as the United States, Europe, and Asia.

Development of Pharmaceutical Drugs for the Treatment of Autoimmune Diseases

Financial Performance (Year ended December 31, 2024):

• Revenue: $0
• Operating Loss: $(940) thousand
• Key Growth Drivers: Not applicable, as XTL Biopharmaceuticals Ltd. is no longer actively involved in drug development following the sublicense of hCDR1 in March 2025.

Product Portfolio:

• hCDR1 (Edratide), a novel synthetic peptide, was previously developed for the potential treatment of systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS).
• rHuEPO was a drug candidate for multiple myeloma, but XTL Biopharmaceuticals Ltd. does not anticipate conducting material research and development activities for it.

Market Dynamics: Not applicable for future operations, as XTL Biopharmaceuticals Ltd. has exited active drug development.

International Operations & Geographic Analysis

Revenue by Geography: The filing indicates that The Social Proxy Ltd. operates in the United States, Europe, and Israel, and that a criterion for its beneficial tax rate as a Preferred Technology Enterprise is "significant revenues from sales outside of Israel." However, specific revenue figures by individual regions or countries are not disclosed.

International Business Structure:

• Subsidiaries: XTL Biopharmaceuticals Ltd. has two wholly-owned subsidiaries: The Social Proxy Ltd. and Xtepo Ltd., both incorporated in Israel.
• Licensing Agreements: XTL Biopharmaceuticals Ltd. holds a license from Yeda Research and Development Company Ltd. (Israel) for hCDR1, which has been sublicensed exclusively worldwide to Biossil Inc. (Canada).

Cross-Border Trade: The Social Proxy Ltd.'s business model inherently involves cross-border trade by providing web data collection services globally. Its eligibility for a beneficial tax rate as a Preferred Technology Enterprise in Israel is contingent on generating significant revenues from sales outside of Israel and deriving income from IP developed in Israel for exports. The company's operations rely on third-party internet service providers, proxy network providers, data center proxy providers, and mobile carriers, which implies international supply chain dependencies.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No share repurchases were disclosed.
• Dividend Payments: XTL Biopharmaceuticals Ltd. has never declared or paid any cash dividends on its ordinary stock and does not anticipate paying any in the foreseeable future.
• Dividend Yield: 0%
• Future Capital Return Commitments: No specific future capital return commitments were disclosed.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $371 thousand
• Total Debt: $138 thousand (comprising $132 thousand in short-term loans and $6 thousand in credit from banking corporations)
• Net Cash Position: $233 thousand
• Debt Maturity Profile: The short-term loan of $132 thousand is repaid monthly over a 12-month period and bears an annual interest of 12%.

Cash Flow Generation (Year ended December 31, 2024):

• Operating Cash Flow: $(1,618) thousand (net cash used in operating activities)
• Free Cash Flow: Not explicitly stated, but negative given the operating cash flow and capital expenditures.
• Cash Conversion Metrics: Not explicitly disclosed.

Currency Management: As of December 31, 2024, XTL Biopharmaceuticals Ltd.'s cash and cash equivalents were denominated in U.S. dollars ($343 thousand) and New Israeli Shekels ($28 thousand). The company's treasury risk management policy is to hold NIS-denominated cash and short-term deposits in an amount sufficient to cover anticipated NIS-denominated liabilities for six to twelve consecutive months. XTL Biopharmaceuticals Ltd. may also enter into currency hedging transactions to mitigate foreign exchange risk.

Operational Excellence

Production & Service Model: The Social Proxy Ltd. develops, operates, and distributes its web data extraction platform. Its service model is built on proprietary 5G and 4G mobile private proxies, which are developed using in-house hardware and proprietary software. The operational philosophy emphasizes ethical, secure, fast, reliable, and cost-effective proxy services, leveraging Carrier-Grade Network Address Translation (CGNAT) technology. Operations are conducted within server farms, utilizing ultra-fast fiber optic infrastructure to ensure high speed and maximum available uptime.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Internet Service Providers (ISPs), Proxy Network Providers, Data Center Proxy Providers, and Mobile Carriers: These third-party entities are critical for providing access to residential, mobile, and rotating proxies, which are essential to The Social Proxy Ltd.'s business model.
• Third-party vendors: Used for manufacturing and supplying components, such as modems, for the company's devices.

Facility Network:

• Manufacturing: In-house hardware development for its proprietary proxy solutions.
• Research & Development: Ongoing R&D efforts are conducted to continuously evolve and enhance its proxy and data extraction technologies.
• Distribution: The company's proxy server network is geographically diverse, with deployments in the United States (New York, Florida, and Texas), Europe (Germany, Austria, the United Kingdom), and Israel.

Operational Metrics: While specific quantitative operational metrics like capacity utilization or efficiency measures are not disclosed, the company highlights its ability to provide "unlimited Internet Protocol addresses" and "outperforming traditional solutions in speed and efficiency" as key operational advantages.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Digital Platforms: The Social Proxy Ltd. offers its services through cloud-enabled software subscriptions and various API feeds (Professional Data API, Social Scraper API, SERP API), indicating a strong digital and platform-based distribution approach.
• Channel Partners: While not explicitly detailed, the company's strategy includes leveraging strategic partnerships and alliances for market expansion.

Customer Portfolio: Enterprise Customers: The Social Proxy Ltd. targets and serves a diverse clientele, including data companies, AI-driven businesses, and technology innovators across various sectors (e.g., finance, e-commerce, marketing).

• Customer Concentration: No specific customer concentration metrics are disclosed.

Regional Market Penetration: The Social Proxy Ltd. has established a presence with proxy servers in key regions including the United States (New York, Florida, and Texas), Europe (Germany, Austria, the United Kingdom), and Israel. Its strategy aims for continued global network expansion, particularly in high-demand regions such as the United States, Europe, and Asia.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The data collection, web scraping, and proxy services industry is characterized by intense competition, continuous innovation, and evolving security threats. It is driven by the increasing demand for real-time data extraction, cybersecurity solutions, and AI-driven analytics. The global data collection and labeling market was valued at $3.77 billion in 2024 and is projected to grow at a CAGR of 28.4% from 2025 to 2030, reaching $17.1 billion. Key trends include a growing demand for privacy-first, compliant proxy solutions, emphasis on transparency, legal compliance, and cybersecurity resilience, alongside increasing regulatory scrutiny and the development of sophisticated anti-scraping mechanisms.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Bright Data Ltd. (formerly Luminati): A market leader known for operating one of the most extensive residential proxy networks, positioning itself as a trusted provider for large-scale data collection.
• Oxylabs: Focuses on AI-driven scraping solutions and legal compliance, actively engaging in court cases to validate web scraping practices.
• Smartproxy: Offers cost-effective proxy solutions tailored for smaller businesses and individual users.
• NetNut (a subsidiary of Alarum Technologies Ltd.): Distinguishes itself in enterprise proxy services by leveraging direct partnerships with internet service providers (ISPs) for high-speed and stable connections.

Regional Competitive Dynamics: The competitive landscape is shaped by regulatory challenges and legal considerations, such as GDPR and CCPA, which influence industry practices and compliance requirements. Competitors that proactively align with evolving compliance frameworks are expected to gain a competitive advantage.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics: The company operates in a rapidly evolving industry, and its sales growth is dependent on the continued development of the data collection and proxy services markets. Failure to adapt to constant innovation, evolving security threats, or changing customer requirements could adversely affect the business. Geopolitical Instability: XTL Biopharmaceuticals Ltd.'s operations in Israel expose it to political, economic, and military instability in Israel and the Middle East, which could materially and adversely affect its business, financial condition, and ability to raise capital. Commercial insurance typically does not cover losses from such events. Economic Uncertainty: Global economic volatility and disruption, including geopolitical tensions (e.g., Russia-Ukraine conflict) and trade policies (e.g., tariffs), could adversely affect the company's business, financial condition, and operating results.

Operational & Execution Risks

Global Supply Chain Vulnerabilities: The business model relies heavily on agreements with third-party internet service providers (ISPs), proxy network providers, data center proxy providers, and mobile carriers. Termination of these agreements, service restrictions, or legal/regulatory challenges faced by these third parties could impact service delivery and increase costs. Regulatory Compliance: Increasing regulatory scrutiny of web data collection (e.g., GDPR, CCPA, CFAA) and data localization/sovereignty laws (e.g., China, Russia, India, EU) pose significant compliance costs and risks of fines, injunctions, or operational restrictions. Anti-Scraping Mechanisms: The proliferation of sophisticated anti-scraping technologies by websites (e.g., bot detection, CAPTCHA systems, fingerprinting, access blocking) may significantly restrict the company's ability to collect publicly available data. Management & Personnel: The company depends on its senior management team and key personnel. Management turnover or inability to attract and retain additional qualified personnel, particularly in sales, could harm the business and its growth trajectory. Rapid expansion could also strain personnel resources and infrastructure. Acquisition Risks: Future acquisitions may lead to equity dilution, significant cash outlays, and operational risks such as integration difficulties, inability to retain key personnel, exposure to legal claims, diversion of management attention, and potential impairment of goodwill.

Financial & Regulatory Risks

Liquidity and Capital Requirements: XTL Biopharmaceuticals Ltd. has incurred significant losses and negative cash flows from operations, with an accumulated deficit of $159,009 thousand as of December 31, 2024. Management has concluded there is substantial doubt about its ability to continue as a going concern, necessitating additional financing through equity offerings, debt, or capital inflows, which may not be available on acceptable terms. Foreign Exchange Risk: Exposure to U.S. dollar devaluation against the New Israeli Shekel (NIS) and other currencies due to international operations and expenses. PFIC Status: There is a significant risk that XTL Biopharmaceuticals Ltd. will be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which would subject U.S. holders of its ordinary shares to special, potentially adverse, tax rules. Nasdaq Delisting Risk: Failure to maintain compliance with Nasdaq's continued listing standards (e.g., minimum bid price, stockholders' equity) could lead to delisting, making it more difficult for investors to sell shares and impairing capital raising efforts. Israeli Legal Framework: Provisions of Israeli law, including those governing mergers, tender offers, and tax considerations, may delay, prevent, or impede a change of control, even if favorable to shareholders. Enforcing U.S. judgments or non-compete covenants in Israel may also be difficult.

Innovation & Technology Leadership

Research & Development Focus: XTL Biopharmaceuticals Ltd., through The Social Proxy Ltd., is committed to continuous development and enhancement of its proxy and data extraction technologies. Global R&D Network: The company's R&D efforts are focused on its proprietary 5G and 4G mobile proxy solutions, advanced API integrations, automation features, and AI-powered scrapers (Professional Data API, Social Scraper API, and SERP API). The development roadmap includes improvements in proxy rotation mechanisms, security enhancements, and expanded global reach.

Intellectual Property Portfolio:

• Patent Strategy: XTL Biopharmaceuticals Ltd. actively files patent applications in the U.S. and internationally and relies on trade secrets, technical know-how, and innovation to protect its competitive position.
• Patent Holdings: The hCDR1 asset, previously licensed from Yeda Research and Development Company Ltd., included three families of patents (e.g., "Synthetic Human Peptides and Pharmaceutical Compositions Comprising Them" for SLE), which have now been sublicensed to Biossil Inc. The Social Proxy Ltd. currently relies on specific rare know-how and internal developments of hardware and software, without registered patents.
• Licensing Programs: The Exclusive Sublicense Agreement with Biossil Inc. for hCDR1 is a key IP monetization strategy, with potential cumulative payments of up to $11.5 million.
• IP Litigation: The company faces risks from third-party claims of intellectual property infringement and challenges to its patent rights.

Technology Partnerships: XTL Biopharmaceuticals Ltd. aims to drive growth through strategic alliances and partnerships, aligning its data solutions with the needs of large enterprises, AI-driven businesses, and technology innovators.

Leadership & Governance

Executive Leadership Team

International Management Structure: The executive leadership team includes individuals with experience in both Nasdaq and TASE listed companies, indicating exposure to international business environments. The Chief Financial Officer is a partner at an accounting firm and dedicates approximately 9 hours per week to XTL Biopharmaceuticals Ltd.

Board Composition: The Board of Directors consists of five members, including two external directors (Osnat Hillel Fain and Iris Shapira Yalon) who meet the requirements of the Israeli Companies Law. XTL Biopharmaceuticals Ltd. complies with Nasdaq's director independence requirements. The board has an Audit Committee (chaired by Osnat Hillel Fain, who is an audit committee financial expert), a Compensation Committee (chaired by Osnat Hillel Fain), and a Nomination Committee.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: XTL Biopharmaceuticals Ltd. operates under the Israeli Companies Law and is subject to the U.S. Securities Act and the Exchange Act. Its web data collection subsidiary, The Social Proxy Ltd., navigates a rapidly evolving regulatory landscape, including the European Union’s General Data Protection Regulation (GDPR), the California Consumer Privacy Act (CCPA), and the Computer Fraud and Abuse Act (CFAA) in the United States. The company is also subject to data localization and sovereignty laws in various jurisdictions, including China, Russia, India, and the European Union.

Cross-Border Compliance:

• Export Controls: XTL Biopharmaceuticals Ltd. is subject to U.S. and Israeli export control and economic sanctions laws, which restrict the delivery and sale of certain products to embargoed or sanctioned countries, governments, and persons.
• Sanctions Compliance: The company must monitor and comply with multi-jurisdictional sanctions.
• Anti-Corruption: Not explicitly detailed, but generally implied for international operations.

International Tax Strategy:

• Corporate Tax Rates: XTL Biopharmaceuticals Ltd. and its subsidiary Xtepo Ltd. are subject to a corporate tax rate of 23% in Israel. The Social Proxy Ltd. is expected to qualify for a beneficial tax rate of 12% as a "Preferred Technology Enterprise" (PTE) in Israel, provided it meets specific criteria related to R&D investment, innovative products, significant non-Israeli revenues, and IP developed in Israel for exports. The Social Proxy Inc and Social Proxy LDA are subject to a corporate tax rate of 21% in the United States and Portugal, respectively.
• Transfer Pricing: The company's international tax strategy involves managing inter-company transactions and policies, which are subject to transfer pricing regulations.
• Tax Treaties: Tax treaties, such as the U.S.-Israel Tax Treaty, influence capital gains and dividend taxation for non-Israeli residents.
• BEPS Compliance: Not explicitly detailed.

Currency Management & Financial Strategy

Multi-Currency Operations: XTL Biopharmaceuticals Ltd. conducts operations in multiple currencies, with its functional currency being the U.S. dollar. Currency Exposure (as of December 31, 2024):

Hedging Strategies: XTL Biopharmaceuticals Ltd. may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in exchange rates. Its treasury risk management policy includes a natural hedge by holding NIS-denominated cash and cash equivalents to match anticipated NIS-denominated liabilities.